Contributions of human tumor xenografts to anticancer drug development

Cancer Research

Volumn 66, Issue 7, 2006, Pages 3351-3354

  Sausville, Edward A ^a   Burger, Angelika M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

DNA DAMAGE; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR XENOGRAFT; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MICE; MICE, SCID; MICE, TRANSGENIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33645734205     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3627     Document Type: Review

References (21)

1. Gura T. Cancer Models: systems for identifying new drugs are often faulty. Science 1997;278:1041-2.
2. Leaf C, The war on cancer: the models of cancer stink. Fortune 2004;149:76-88.
3. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary asperillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002;46:12-23.
4. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi JW, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003;4:181-9.
5. Suggit M, Bibby MC, 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 2005;11:971-81.
6. Alley MC, Hollingshead MG, Dykes DJ, Waud WR. Human tumor xenograft models in NCI drug development. In: Teicher BA, Andrews PA, editors. Anticancer drug development guide: preclinical screening, clinical trials, and approval. 2nd ed. Totowa (NJ): Humana Press, Inc; 2004. p. 125-52.
7. Burger AM, Fiebig HH. Screening using animal systems. In: Baguley BC, Kerr DJ, editors. Anticancer drug development, San Diego (CA): Academic Press; 2001. p. 285-97.
8. Ishii S, Nagasawa M, Kariya Y, Yamamoto H. Selective cytotoxicity of brefeldin A against human tumor cell lines. J Antibiotics 1989;42:1877-8.
9. Volpe DA, Tomaszewski JE, Parchment R, et al. Myelotoxic effects of the bifunctional alleviating agent bizelesin on human, canine, and murine myeloid progenitor cells. Cancer Chemother Pharmacol 1996;39:143-9.
10. Scott AM, Wiseman G, Welt S, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003;9:1639-47.
11. Fiebig HH, Burger AM. Human tumor xenografts and expiants. In: Teicher BA, editor. Animal models in cancer research. Totowa (NJ): Humana Press, Inc; 2001. p. 113-37.
12. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models an early clinical trials. Br J Cancer 2001;84:1424-31.
13. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-39.
14. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumor xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004;40:802-20.
15. Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 2004;40:837-44.
16. Mi Z, Burke TG. Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency domain fluorescence spectroscopic study. Biochemistry 1994;33:12540-5.
17. Decker S, Holfingshead M, Bonomi CA, Carter JP, Sausville EA. The hollow fibre model in cancer drug screening: the NCI experience. Eur J Cancer 2004;40:821-6.
18. Shnyder SD, Hasan J, Cooper PA, et al. Development of a modified hollow fibre assay for studying agents targeting the tumor neovasculature. Anticancer Res 2005;25:1889-94.
19. Tan M, Fang HB, Tian GL, Houghton PJ. Repeated measures models with constrained parameters for incomplete data in tumour xenograft experiments. Stat Med 2005;24:109-19.
20. EORTC Laboratory Research Division [no authors listed]. European Organization for Research and Treatment of cancer (EORTC) Laboratory Research Division workshop on the role of in vivo preclinical models in the development of contemporary cancer therapeutics, Verona, Italy, 3 February 2001. Eur J Cancer 2001;37:1976-80.
21. Adams J, Palombella VJ, Sausville EA, et al. Proteosome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.